<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-036272</identifier>
<setSpec>1575-0922</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Use of glargine before pregnancy</dc:title>
<dc:description xml:lang="en">We present the case of a 34-year-oldwoman diagnosed with type 1 diabetes mellitus who had been on intensive therapy since the age of 15 years. The patient was enrolled in a clinical trial using insulin glargine and, despite recommendations, became pregnant. Due to the lack of safety data on insulin glargine during pregnancy, we recommended that she change her evening glargine to insulin NPH distributed into three doses and continue with the pre-meal lispro analogue. Because the patient had experienced a lower frequency of nocturnal hypoglycemia and her quality of life had improved during the clinical trial, she decided to continue with the long-acting insulin at bedtime. The course of the pregnancy and postpartum were normal. To date the experience published on glargine in pregnancy is limited. In our case, treatment with insulin glargine in the periconceptional period achieved optimal metabolic control with no maternal or fetal complications (AU)</dc:description>
<dc:creator>García, A</dc:creator>
<dc:creator>Pérez, C</dc:creator>
<dc:creator>Rodríguez, C</dc:creator>
<dc:creator>Azriel, S</dc:creator>
<dc:creator>Hawkins, F</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Presentamos el caso de una mujer de 34 años diagnosticada de diabete smellitus tipo 1 en terapia intensiva desde los 15 años. La paciente fue incluida en un ensayo clínico con insulina glargina. A pesar de las recomendaciones, la paciente se quedó embarazada. Debido a la falta de seguridad de la insulina glargina en la gestación, se recomendó un cambio de pauta terapéutica manteniendo el análogo lispro preingestas  y NPH en 3 dosis. La paciente decidió continuar con la insulina glargina por presentar un menor número de hipoglucemias nocturnas y una clara mejoría de su calidad de vida. Tanto el embarazo como el posparto cursaron con normalidad. Hasta ahora, la experiencia con insulina glargina durante la gestación es limitada. En nuestro caso, el tratamiento con insulina glargina en el período periconcepcional consiguió la optimización del control metabólico sin complicaciones maternas nifetales (AU)</dc:description>
<dc:source>Endocrinol Nutr;52(3): 143-145, mar. 2005.</dc:source>
<dc:identifier>ibc-036272</dc:identifier>
<dc:title xml:lang="es">Uso de insulina glargina en el período preconcepcional</dc:title>
<dc:subject>^d22261</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d7500^s22000</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d11731^s22045</dc:subject>
<dc:subject>^d3944^s22057</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d3944^s22012</dc:subject>
<dc:subject>^d11696^s22057</dc:subject>
<dc:type>article</dc:type>
<dc:date>200503</dc:date>
</metadata>
</record>
</ibecs-document>
